Skip to content

Cristiana Stefan

3 papers in the library · 32 citations · publishing 2019-2026

Papers

Sort Most recent Most cited

Global emergence and γ-aminobutyric acid type A (GABAA) receptor activity of the new designer benzodiazepine ethylbromazolam

Archives of Toxicology May 20, 2026 Caitlyn Norman, Dean Acreman, Meera Bissram et al.

Abstract Designer benzodiazepines (DBZDs) are a class of new psychoactive substances (NPS) designed as legal alternatives to prescription BZDs. Bromazolam has been the most prevalent DBZD detected on the recreational market around the world; however, a new DBZD, ethylbromazolam (8-bromo-1-ethyl-6-phenyl-4 H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; also known as bromoethylazolam) has recently...

DOI: 10.1007/s00204-026-04433-9 (opens in new tab) Full text (opens in new tab) Benzodiazepine Designer drug In vitro toxicology Medical prescription +8

Combined effect of alcohol and cannabis on simulated driving.

Psychopharmacology May 2022 Andrew Fares, Christine M Wickens, Robert E Mann et al.

With alcohol and cannabis remaining the most commonly detected drugs in seriously and fatally injured drivers, there is a need to understand their combined effects on driving. The present study examined the effects of combinations of smoked cannabis (12.5% THC) and alcohol (target BrAC 0.08%) on simulated driving performance, subjective drug effects, cardiovascular measures, and self-reported...

Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis

Brain July 3, 2019 Anthony Feinstein, Cecilia Meza, Cristiana Stefan et al. 32 citations

Cognitive dysfunction affects 40-80% of patients with multiple sclerosis. Smoking cannabis may add to these deficits. It is unclear whether coming off cannabis results in cognitive improvement. To address this question, 40 patients with multiple sclerosis who started using cannabis after the onset of multiple sclerosis and who used it for at least 4 days a week over many years were divided by...